|
Emerging Asthma Agents That Offer the Convenience of Once-Daily Dosing Will …
MarketWatch (press release) The findings from the Pharmacor topic entitled Asthma reveal that Relovair will emerge as the market leader among once-daily LABA/ICS combinations as GlaxoSmithKline wages an aggressive campaign to switch patients off of Advair/Seretide/Adoair prior to … |
View full post on asthma – Google News